Overactive Bladder - Results from #1700

Urodynamic pattern distribution among aged male patients with lower urinary tract symptoms suggestive of bladder outlet obstruction - Abstract April 17, 2014

Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study - Abstract April 16, 2014

Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: Results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial - Abstract April 15, 2014

The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis - Abstract April 14, 2014

Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder - Abstract April 11, 2014

The multidimensional sensation of desire to void differs between people with and without overactive bladder - Abstract April 10, 2014

Intradetrusor onabotulinumtoxinA for overactive bladder - Abstract April 9, 2014

Mirabegron in the treatment of overactive bladder - Abstract April 8, 2014

Reproductive history and progression of lower urinary tract symptoms in women: Results from a population-based cohort study - Abstract April 8, 2014

Longitudinal changes in overactive bladder and stress incontinence among parous women - Abstract April 4, 2014

Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice - Abstract April 3, 2014

Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) - Abstract April 2, 2014

Improving the clinical prediction of detrusor overactivity by utilizing additional symptoms and signs to overactive bladder symptoms alone - Abstract March 31, 2014

Critical analysis of phase 2 and 3 randomized control trials (RCTs) evaluating efficacy and tolerability of a ß3 -adrenoceptor agonist (Mirabegron) for overactive bladder (OAB) - Abstract March 28, 2014

Transcutaneous posterior tibial nerve stimulation: Evaluation of a therapeutic option in the management of anticholinergic refractory overactive bladder - Abstract March 28, 2014

Overactive bladder changes with time - a five-year longitudinal follow-up of the changes of overactive bladder symptoms, urodynamic studies, and urinary nerve growth factor levels - Abstract March 27, 2014

The psychological impact of overactive bladder: A systematic review - Abstract March 26, 2014

Clinical and video urodynamic characteristics of adult women with dysfunctional voiding - Abstract March 24, 2014

Women's perspective: Intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment - Abstract March 22, 2014

Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents? - Abstract March 21, 2014

Page 86 of 122